Immunotherapy before surgery for esophageal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests whether giving an immunotherapy drug called tislelizumab before surgery helps shrink esophageal cancer and improve outcomes. It is for people newly diagnosed with early-stage squamous cell esophageal cancer that can be removed surgically.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- You must have a specific type of esophageal cancer called squamous cell carcinoma that has not spread beyond your chest or nearby lymph nodes and can be removed by surgery.
- You have not had any prior treatment for this cancer (no surgery, chemotherapy, radiation, or immunotherapy).
- You should be in good overall health, able to care for yourself and perform daily activities (ECOG score 0-1).
- You must have normal blood, liver, kidney, and clotting tests (these will be checked before you join).
- Women who could become pregnant must have a negative pregnancy test and use birth control during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether combining the immunotherapy drug tislelizumab with chemotherapy before and after surgery helps treat esophageal squamous cell cancer better than just surgery alone. It aims to shrink the tumor before surgery and reduce the chance of the cancer coming back afterward.
This study tests a new immunotherapy drug (tislelizumab) combined with chemotherapy before either surgery or radiation for esophageal cancer. The goal is to see if this combination helps shrink the tumor and improves outcomes, and it may offer a promising option for patients who meet the criteria.
This trial tests a combination of treatments given before surgery to shrink tumors in patients with esophageal cancer that is considered too advanced for immediate surgery. The goal is to make surgery possible and improve outcomes.
This trial tests a combination of low-dose radiation, chemotherapy, and immunotherapy before surgery for esophageal cancer. The goal is to see if this approach helps shrink the tumor and improve outcomes.
This trial tests a combination of three medicines (immunotherapy plus two chemotherapy drugs) given before surgery to shrink esophageal cancer. The goal is to make the tumor smaller and easier to remove completely, potentially improving the chance of a cure.
This trial tests a combination of chemotherapy, immunotherapy, and a type of radiation that avoids nearby lymph nodes, given before surgery for a specific stage of esophageal cancer. The goal is to see if this approach can improve outcomes and make surgery more effective.
Hear when a new Esophagus Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.